Company Description
Rapport Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule medicines for patients suffering from central nervous system (CNS) disorders.
Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder.
The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders.
Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts.
| Country | United States |
| Founded | 2022 |
| IPO Date | Jun 7, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 58 |
| CEO | Abraham Ceesay |
Contact Details
Address: 1325 Boylston Street, Suite 401 Boston, Massachusetts 02215 United States | |
| Phone | 857 321 8020 |
| Website | rapportrx.com |
Stock Details
| Ticker Symbol | RAPP |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0002012593 |
| ISIN Number | US75383L1026 |
| Employer ID | 88-0724208 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Abraham N. Ceesay M.B.A. | Chief Executive Officer, President, Treasurer and Director |
| Dr. Steven M. Paul M.D. | Founder and Independent Chairman |
| Dr. Troy A. Ignelzi | Chief Financial Officer |
| Cheryl Gault | Chief Operating Officer |
| David Bredt M.D., Ph.D. | Founder and Chief Scientific Officer |
| Karina Chmielewski | Chief Information Officer and Head of Operations |
| Julie DiCarlo | Head of Communications and Investor Relations |
| Kathleen A. Wilkinson | Chief People Officer |
| Dr. Bradley S. Galer M.D. | Chief Medical Officer |
| Swamy Yeleswaram Ph.D. | Chief Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 13, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 7, 2024 | 10-Q | Quarterly Report |
| Nov 7, 2024 | 8-K | Current Report |
| Oct 18, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Aug 8, 2024 | 10-Q | Quarterly Report |
| Aug 8, 2024 | 8-K | Current Report |
| Jul 10, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |